As we move beyond the era of digital transformation (DX), where industries and workflows were reshaped through digital technologies, a new age of rapid AI adoption—often referred to as the era of AI Transformation (AX)—is emerging. AI is increasingly applied across daily life and industrial sectors, exerting growing influence in multiple domains.

The healthcare industry is one of the sectors undergoing the fastest transformation with AI integration. Digital healthcare has led to AI-powered diagnostic and treatment solutions, introducing a new paradigm within medical practice.

Amid this rapid growth, AIDOT has been at the forefront of exploring new possibilities in medical diagnostics through AI, building its expertise and competitive advantage. CEO Jaehun Jung shared insights into AIDOT’s journey and vision for global medical AI.

Could you introduce AIDOT?

AIDOT is a healthcare AI company specializing in diagnostic support software for diseases such as cervical cancer, urinary stones, and otitis media. Our solutions are applied not only in Korea but also in the U.S., Southeast Asia, and Latin America, with active commercialization and clinical implementation ongoing.

Initially, AIDOT focused on software development for IT-based services and new solutions. With the emergence of AI technologies like AlphaGo, interest in AI surged, and we began collaborating with university hospital professors to integrate AI into cervical cancer diagnostics. This led to the development of a dedicated AI solution through national research projects, establishing AIDOT as a leader in medical AI business.

Our mission is to provide accurate and efficient medical services through AI, ensuring that even regions with limited healthcare access can benefit from precise diagnostics. We are committed to continuous technological development and healthcare innovation to improve lives globally.

What are your main products and services?

Currently, AIDOT offers several AI-powered diagnostic solutions:

• Cerviray AI – a remote cervical examination AI system supporting cervical cancer screening.

• URO dot AI – a CT-based solution that automatically detects and measures urinary stones.

• ECHO dot AI – an AI system analyzing the severity of otitis media.

Cerviray AI uses a portable digital colposcope and is the only solution in Korea capable of classifying cervical lesions into four grades and marking the exact lesion locations with AI. It provides fast and accurate remote diagnostics and has already been commercialized in more than ten countries, with ongoing expansion.

URO dot AI is recognized as an integrated innovative device for urinary stone diagnosis and is commercially available in Korea as a non-reimbursed product. Upgrades to X-ray-based diagnostics are underway, and interest from Southeast Asia and Europe continues to grow.

ECHO dot AI was developed to prevent misdiagnosis between colds and otitis media, enabling early detection even outside ENT clinics. It targets primary care and pediatric clinics and is preparing for commercialization.

Our main products are expanding not only in Korea but also in Southeast Asia, Latin America, and the U.S., where FDA approval has been obtained. Clinical studies in Indonesia are complete, and commercialization will begin next year, while Thailand has already granted regulatory approval within a year and a half of market entry.

What are AIDOT’s key strengths?

From the outset, AIDOT has focused on solutions combining hardware devices and AI algorithms. We developed proprietary know-how for preprocessing unstructured image data to optimize AI learning. This has resulted in uniquely high accuracy and device-optimized AI performance, forming our core competitive advantage.

We also implemented lightweight AI technology to ensure our solutions function in regions with limited infrastructure. Even with basic hardware or low-tech medical environments, our devices perform seamlessly and can analyze data offline, making them ideal for mobile and field diagnostics. These lightweight solutions have been well received in public health centers, NGO projects, and international telemedicine deployments. We have also developed strong security measures to protect medical and personal data.

These technical strengths give AIDOT’s products a competitive edge in global markets.

What are your future goals?

Our vision goes beyond product supply: we aim to transform national public health systems using AI. By leveraging FDA approvals and global partnerships, we plan to achieve over 70% of revenue from overseas markets by 2030, reinforcing Korea’s leadership in medical AI technology globally.

AI, in our view, is more than automation—it can become a new standard in healthcare. AIDOT plans to expand beyond cervical cancer to cover diverse diseases, building a comprehensive AI diagnostic platform and a “companion AI” that supports clinicians in making faster and more accurate decisions. We are committed to continuous R&D to become a trusted K-medical AI company worldwide.

Finally, running a startup is never easy. While many companies focus primarily on revenue, AIDOT prioritizes social impact and technology that helps people. We aim to contribute to healthier lives, especially in regions with limited medical access, ensuring our solutions create tangible benefits for global communities.

Economic News / November 28, 2025 / Reporter Myungji Park